NasdaqGS · Biotechnology

OptiNose (OPTN)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Not covered

Ratings unavailable

$9.60Price unavailableCached market snapshot

Market cap$97.2M

Cash$72.9M

Quarterly burn$8.6M

Pipeline assets2

Short float2.1%

Latest coverage

News & Press Releases

External sources

Aug 18, 2026

National Kidney Registry, National Liver Registry Ensuring Transplant Centers Can Meet OPTN Emergency Policy DeadlinePR Newswire

Aug 10, 2026

National Kidney Registry & National Liver Registry Host Second Industry Webinar for Transplant Centers to Prepare for New OPTN Serology Testing RegulationsPR Newswire

Jul 30, 2026

National Kidney Registry & National Liver Registry Hosts Webinar for Transplant Centers to Prepare for New OPTN Serology Testing PolicyPR Newswire

Company profile

About OptiNose

OptiNose is a biotechnology company in the healthcare sector.

Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.